

Selected References for Diabetes Care

I. References Helpful to Primary Care Providers:

A. General Diabetes Care

1. American Diabetes Association: Clinical Practice Recommendations. *Diabetes Care* vol 22 (Suppl. 1), 1999. (To order call 1-800-232-3472).
2. American Diabetes Association: *Intensive Diabetes Management*, 2nd ed., 1998.
3. American Diabetes Association: *Medical Management of Type 1 Diabetes*, 3rd ed., 1998.
4. American Diabetes Association: *Medical Management of Type 2 Diabetes*, 4th ed., 1998.
5. American Diabetes Association: *Therapy for Diabetes Mellitus and Related Disorders*, 3rd ed., 1998.
6. Department of Health & Human Services, Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation: *The Prevention and Treatment of Complications of Diabetes: A Guide for Primary Care Practitioners*, 1991.
7. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977-986, 1993.
8. Levetan C, Ratner R: The economic bottom line on preventive diabetes care. *Practical Diabetology*, 10-19, Dec. 1995.
9. UK Prospective Diabetes Study (UKPDS): Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33) *Lancet* 352:837-853, 1998.

II. References Used to Support the Inclusion of the Specific Items in the Guidelines:

A. Blood Pressure

1. American Diabetes Association: Treatment of hypertension in diabetes. *Diabetes Care* 16:1394-1401, 1993.
2. Foote A, et al.: Benefit to cost ratio of work-site blood pressure control program. *JAMA* 265:1283-1286, 1991.
3. Hanson L, et al: Results of the hypertension optimal treatment (HOT) randomized trial. *Lancet* 351:1755-1762, 1998.
4. *The Sixth Report of the JNC*. NIH-NHLBI, 1997.
5. UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. *Lancet* 352:854-965, 1998.

B. Foot Exam

1. Apelqvist J, et al: Diabetic foot ulcers in a multidisciplinary setting: An economic analysis of primary healing and healing with amputation. *J Intern Med* 235:463-471, 1994.
2. Caputo GM, et al: Assessment and management of foot disease in patients with diabetes. *N Engl J Med* 331:854-860, 1994.
3. Litzelman DK, et al: Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. *Ann Intern Med* 119:36-41, 1993.

C. Dilated Eye Exam

1. American Academy of Ophthalmology: *Preferred Practice Pattern Diabetic Retinopathy*, 1998.
2. American Diabetes Association: Diabetic Retinopathy. *Diabetes Care* vol 22 (Suppl. 1):S70-S73, 1999.
3. American Diabetes Association: Technical Review: Diabetic Retinopathy. *Diabetes Care* 21(1):143-156, 1998.
4. Dasbach EJ, et al: Cost-effectiveness of strategies for detecting diabetic retinopathy. *Medical Care* 29:20-39, 1991.
5. Javitt JC, et al: Preventive eye care in people with diabetes is cost-saving to the federal government: Implications for health-care reform. *Diabetes Care* 17(8):909-917, 1994.
6. Singer DE, et al: Screening for diabetic retinopathy. *Ann Intern Med* 116:660-671, 1992.

D. Depression

1. Gavard JA, et al.: Prevalence of depression in adults with diabetes: An epidemiological evaluation. *Diabetes Care* 16:1157-1178, 1993.
2. Lustman PJ, et al.: Cognitive behavior therapy for depression in type 2 diabetes mellitus. *Ann Intern Med* 129:613-620, 1998.
3. Lustman PJ, et al.: Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial. *Psychosom Med* 59:241-250, 1997.

E. HbA1c

1. Abaira C, et al.: Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). *Diabetes Care* 18(8):1113-1123, 1995.
2. The DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): Design and methodological considerations for the feasibility phase. *Diabetes* 35:530-545, 1986
3. The DCCT Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. *Diabetes* 44:968-983, 1995.
4. Goldstein DE, et al.: Is glycohemoglobin testing useful in diabetes mellitus? Lessons from the Diabetes Control and Complications Trial. *Clin Chem* 40:1637-1640, 1994.
5. Larsen ML, et al: Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. *N Engl J Med* 323:1021-1025, 1990.
6. UK Prospective Diabetes Study (UKPDS): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. *Lancet* 352:854-965, 1998.

F. Microalbuminuria (albumin/creatinine ratio)

1. Bennett PH, et al: Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. *Am J Kidney Dis* 25:107-112, 1995.
2. Borch-Johnson K, et al: Is Screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? *BMJ* 306:1722-1725, 1993.
3. Lewis JB: Microalbuminuria: accuracy or economics. *Am J Kid Dis* 32:524-528, 1998.
4. Neil A, et al: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. *Diabetes Care* 16(7):996-1003, 1993.
5. Pegoraro A, et al: Simplified screening for microalbuminuria. *Ann Intern Med* 127:817-819, 1997.
6. Siegel JE, et al: Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. *J Am Soc Nephrol* 3:S111-S119, 1992.

F. Microalbuminuria (albumin/creatinine ratio) (cont)

7. Warram JH, et al: Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. *J Amer Soc Nephrol* 7:930-937, 1996.

G. Total Cholesterol & Triglycerides (for adults)

1. American Diabetes Association: Management of dyslipidemia in adults with diabetes. *Diabetes Care* vol 22 (Suppl. 1): S56-S59, 1999.
2. American Diabetes Association: Detection and management of lipid disorders in diabetes. *Diabetes Care* vol 18 (Suppl. 1):S86-S93, 1995.
3. Frost P, Havel R: Rationale for use of non-HDL cholesterol rather than LDL cholesterol as a tool for screening and assessment of risk and therapy. *Am J Cardiol* 81(4A): 26B-31B, 1998.
4. Garg A: Treatment of diabetic dyslipidemia. *Am J Cardiol* 81(4A): 47B-51B, 1998.
5. Grover SA, Coupal L: Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? *JAMA* 274:801-806, 1995.
6. Grundy S: Statin trials and goals of cholesterol-lowering therapy. *Circulation* 97:1442-1445, 1998.
7. Hamilton VH, et al.: The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. *JAMA*. 273:1032-1038, 1995.
8. Law MR, et al: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? *Br Med J* 308:367-373, 1994.
9. Pendersen TR: Reduction in the incidence of major coronary heart disease events in the 4S Study. *Circulation* 97:1453-1460, 1998.
10. Pyorala K: The effect of cholesterol lowering on coronary events and diabetic patients with coronary heart disease. *Diabetes* 44:35A, 1995.
11. Sacks PM, et al: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events. *Circulation* 97:1446-1452, 1998.
12. Shepherd J, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 333:1301-1307, 1995.
13. Smith GD, et al: Cholesterol lowering and mortality: The importance of considering initial level of risk. *Br Med J* 306:1367-1373, 1993.
14. West of Scotland Coronary Prevention Study Group: Influence of pravastatin and plasma lipids on clinical events. *Circulation* 97:1442-1445, 1998.

H. Management Principles and Complications (Psychosocial and Behavioral Issues)

1. American Diabetes Association: National standards for diabetes self-management education programs and American Diabetes Association review criteria. *Diabetes Care* 18(5):737-741, 1995.
2. Anderson RM, et al: Patient empowerment: Results of a randomized controlled trial. *Diabetes Care* 18:943-949, 1995.
3. Clement S: Diabetes self-management education. *Diabetes Care* 18(8):1204-1214, 1995.
4. Jacomson AM: The psychological care of patients with insulin-dependent diabetes mellitus. *N Eng J Med* 334:1249-1253, 1996.
5. Levetan CS, et al: Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. *Amer J Med* 99:22-28, 1995.
6. Lorenz RA, et al: Changing behavior: Practical lessons from the Diabetes Control and Complications Trial. *Diabetes Care* 19(6):648-652, 1996.
7. Rollnick S, Heather N, Bell A: Negotiating behavior change in medical settings: The development of brief motivational interviewing. *J of Mental Health* 1:25-37, 1992.
8. Rubin RR, Peyrot M: Psychosocial problems and interventions in diabetes. *Diabetes Care* 15:1640-1657, 1992.

H. Management Principles and Complications (Psychosocial and Behavioral Issues) (cont)

9. Strowig SM, Basco M, Cercone S: A cognitive behavioral approach to diabetes management. *Diabetes Spectrum* 7:341-342, 1994.
10. Toobert DJ, Glasgow RE: Problem solving and diabetes care. *J of Behavioral Med* 14:71-86, 1991.

I. Medical Nutrition Therapy

1. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus. *Diabetes Care* vol 22 (Suppl. 1):S44-S48, 1999.
2. Franz MJ, et al: Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. *J Am Diet Assoc* 95:1018-1024, 1995.
3. Franz MJ, et al: Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: A randomized, controlled clinical trial. *J Am Diet Assoc* 95:1009-1017, 1995.
4. Monk A, et al: Practice guidelines for medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. *J Am Diet Assoc* 95:999-1006, 1995.

J. Physical Activity

1. American Diabetes Association: Diabetes mellitus and exercise. *Diabetes Care* vol 18 (Suppl. 1):28, 1995.
2. Barnard RJ, et al: Diet and exercise in the treatment of NIDDM. The need for early emphasis. *Diabetes Care* 17(12):1469-1472, 1994.
3. Centers for Disease Control and Prevention: A prospective study of exercise and incidence of diabetes among US male physicians. *JAMA* 268(1):63-67, 1992.
4. Pate RS, et al.: Physical activity and public health: A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. *JAMA* 273:402-407, 1995.

K. Weight Management

1. Colditz GA: Economic costs of obesity. *Am J Clin Nutr* 55:5053-5075, 1992.
2. National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health: *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults*, 1999.
3. Watts NB, et al.: Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. *Arch Intern Med* 150:803-806, 1990.
4. Wing RR, et al.: Long-term effects of modest weight loss in type II diabetic patients. *Arch Intern Med* 147:1749-1753, 1987.
5. Wing RR, et al.: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. *Diabetes Care* 17(1):30-36, 1994.

L. Preconception Counseling & Management

1. American Diabetes Association: Preconception care of women with diabetes. *Diabetes Care* vol 22 (Suppl. 1):S62-S65, 1999.
2. Elixhauser A, et al.: Cost-benefit analysis of preconception care for women with established diabetes. *Diabetes Care* 16(8):1146-1157, 1993.
3. Kitzmiller J, et al.: Preconception care prevents congenital anomalies. *JAMA* 265:731-736, 1991.
4. Metzger BE, Coustan, DR (eds.): Proceedings of the Fourth International Workshop--Conference on Gestational Diabetes Mellitus. *Diabetes Care* vol 21 (Suppl. 2):B1-B167, 1998.
(To order call: 1-619-467-6990).

M. Pregnancy Management

1. American Diabetes Association: Gestational diabetes. *Diabetes Care* vol 22 (Suppl. 2):S74-S76, 1999.
2. American Diabetes Association: *Medical Management of Pregnancy Complicated by Diabetes*, 2nd ed., 1995. (To order call: 1-800-232-3472)
3. Maternal & Child Health Branch, Department of Health Services, State of California: *Guidelines for Care: State Program Guide -- California Diabetes & Pregnancy Program*, 1998. Distributed by Sweet Success Material & Resource Center. (To order call: 1-619-467-4990).
4. Metzger BE, Coustan DR (eds.): Proceedings of the Fourth International Workshop--Conference on Gestational Diabetes Mellitus. *Diabetes Care* vol 21 (Suppl. 2):B1-B167, 1998. (To order call: 1-619-467-6990).
5. Reece EA, Coustan DR: *Diabetes Mellitus in Pregnancy*, 2nd ed. Churchill Livingstone, New York. 1995.

N. Aspirin

1. Colwell JA: Aspirin therapy in diabetes. *Diabetes Care* 20(11):1767-1770, 1997.

O. Smoking Cessation

1. Fortmann SP, Killen JD: Nicotine gum and self-help behavioral treatment for smoking relapse prevention: Results from a trial using population-based recruitment. *J Consult Clin Psychol* 63:460-468, 1995.
2. Wiseman SM, et al.: Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. *Addiction* 90:31-42, 1995.
3. Silagy C, et al.: Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. *Lancet* 343:139-42, 1994.

P. Immunizations

1. American Medical Association: Prevention of Pneumococcal Disease: Use of the Pneumococcal Polysaccharide Vaccine. *Quality Care Alert*, January, 1999.
2. Butler JC, et al: Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. *JAMA* 270(15):1826-1831, 1993.
3. Center for Disease Control: Recommendations of immunization practices advisory committee: Pneumococcal polysaccharide vaccine. *MMWR* 38:64-68, 73-76, 1989.
4. Jacobs RA: General problems in infectious diseases. In *Current Medical Diagnosis & Treatment*, 35th ed. Tierney LM, McPhee SJ, Papadakis MA (eds). Stamford, Appleton & Lange, 29:1130, 1996.
5. Centers for Disease Control: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices(ACIP). *MMWR* 44:1-22, 1995.
6. Centers for Disease Control: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices(ACIP). *MMWR* 46:12-15, 1997.

Q. Dental Exams

1. National Institute of Dental and Craniofacial Research: *Diabetes and Periodontal Disease: A Guide For Patients*, 1997. (To order call 1-301-402-7364 or email: nidr@aerie.com)
2. American Academy of Periodontology: Diabetes and periodontal diseases. *J Periodontol* 67: 166-176, 1996.